Compare · ACTU vs NVO
ACTU vs NVO
Side-by-side comparison of Actuate Therapeutics Inc. (ACTU) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACTU and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 14466.3x ACTU ($12.0M).
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for ACTU).
- NVO has more recent analyst coverage (25 ratings vs 3 for ACTU).
- Company
- Actuate Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $12.0M
- $173.66B
- 1M return
- -
- -10.14%
- 1Y return
- -
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 3
- 4
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ACTU
- Amendment: SEC Form S-1/A filed by Actuate Therapeutics Inc.
- SEC Form FWP filed by Actuate Therapeutics Inc.
- SEC Form S-1 filed by Actuate Therapeutics Inc.
- Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
- President, CEO and Director Schmitt Daniel M converted options into 272,056 shares and covered exercise/tax liability with 120,521 shares, increasing direct ownership by 101% to 301,716 units (SEC Form 4) (for withholding tax)
- Actuate Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
- Actuate Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Zabrowski Dan
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank